Claims
- 1. A method of identifying a compound that binds to a bacterial 70S ribosome or portion thereof, comprising:
designing a compound based upon a three-dimensional structure of the bacterial 70S ribosome said three-dimensional structure defined by structure coordinates within Appendix I; providing said compound; contacting said compound with the bacterial 70S ribosome or portion thereof; and determining whether said compound binds to the bacterial 70S ribosome or portion thereof.
- 2. The method of claim 1, wherein a subset of the structure coordinates within Appendix 1 is used for said designing step.
- 3. The method of claim 1, wherein said portion is a bacterial ribosome 30S subunit.
- 4. The method of claim 1, wherein said portion is a bacterial ribosome 50S subunit.
- 5. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue corresponding to a residue selected from the group consisting of S13 (SEQ ID NO: 36) 92-94, 2-11, S15 (SEQ ID NO: 38) 40-44, 85-89, L2 (SEQ ID NO: 2) 162-164, 172-174, 177-178, 198-202, L5 (SEQ ID NO: 5) 134-153, L14 (SEQ ID NO: 12) 116-119, L19 (SEQ ID NO: 16) 44, 16S rRNA (SEQ ID NO: 45) 1408-1410, 1494, 1495, 784, 785, 794, 1516-1519, 770, 771, 900, 901, 763, 764, 698, 702, 712, 713, 773-776, 345-347, 23S rRNA (SEQ ID NO: 23) 886-888, 1913-1914, 1918, 1836-1836, 1919, 1920, 1922, 1932, 1832-1833, 1947-1948, 1960-1961, 1768-1769, 44-49, 1689-1690, 1989, 1689, 1690, 1702-1705, 1848-1849, and 1896, wherein said 16S rRNA and 23S rRNA residue numbers are according to E. coli numbering.
- 6. The method of claim 5, wherein said residues are selected from the group consisting of S13 (SEQ ID NO: 36) 92-94, 2-11, L5 (SEQ ID NO: 5) 134-153, 16S rRNA (SEQ ID NO: 45) 1408-1410, 1494, 1495, 23S rRNA (SEQ ID NO: 23) 886-888, 1913-1914, and 1918, wherein said 16S rRNA and 23S rRNA residue numbers are according to E. coli numbering.
- 7. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue corresponding to a residue selected from the group consisting of 16S rRNA (SEQ ID NO: 45) 1229, 1338, 1339, 790, 966, 926, 1498, 1400, 530, 1045, 955, 1493, 1339-1340, 1382, 937, 788-789, 693-695, S9 (SEQ ID NO: 32) 128, L5 (SEQ ID NO: 5) 55-66, S13 (SEQ ID NO: 36) 120-122, S12 (SEQ ID NO: 35) 46-48, L16 (SEQ ID NO: 14) 27, 30, S7 (SEQ ID NO: 30) 76-87, 140-152, L1 (SEQ ID NO: 1) 124-128, 52-54, 165-169, 23S rRNA (SEQ ID NO: 23) 1908, 1909, 1922, 1923, 2255-2256, 2252, 2602, 2585, 1913-1915, 881-883, 898, 899, 2470-2472, 2482-2484, 1942, 1943, 2452, 2494, 2553, 2112-2113, 2116, 2117, 1850-1853, 1892, 2235, 2433, 2434, and 199, wherein said 16S rRNA and 23S rRNA residue numbers are according to E. coli numbering.
- 8. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue corresponding to a residue selected from the group consisting of S3 (SEQ ID NO: 26) 127-132, 156-163, S4 (SEQ ID NO: 27) 47-52, S5 (SEQ ID NO: 28) 9-30, 46-56, 16S rRNA (SEQ ID NO: 45), 13-17, 528-532, 1054-1056, 1194-1197, and 1198, wherein said 16S rRNA residue numbers are according to E. coli numbering.
- 9. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue corresponding to a residue selected from the group consisting of 16S rRNA (SEQ ID NO: 45) 685-705, 783-795, 799-802, and 803, wherein said 16S rRNA residue numbers are according to E. coli numbering.
- 10. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue corresponding to a residue selected from the group consisting of L11 (SEQ ID NO: 10) 20-36, 16S rRNA (SEQ ID NO: 45) 54-57, 357-361, and 23S rRNA (SEQ ID NO: 23) 2651-2664, and 2665, wherein said 16S rRNA and said 23S rRNA residue numbers are according to E. coli numbering.
- 11. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue corresponding to a residue selected from the group consisting of L11 (SEQ ID NO: 10) 20-36, 16S rRNA (SEQ ID NO: 45) 54-57, 340-345, 357 -361, and 23S rRNA (SEQ ID NO: 23 )1065-1069, 1094-1097, 2651-2664, and 2665, wherein said 16S rRNA and said 23S rRNA residue numbers are according to E. coli numbering.
- 12. The method of claim 1, wherein said compound is designed to form a non-covalent bond with a residue lining a Shine Dalgamo helix binding pocket, said residue corresponding to a residue selected from the group consisting of S11 (SEQ ID NO: 34) 85-90, 112-129, 22-27, N8 (SEQ ID NO: 41)1-24, and 16S rRNA (SEQ ID NO: 45) 927-93 1, 1388-1393, 1526-1529, 1505-1508, 719-723, and 7 24, wherein said 16S rRNA and residue numbers are according to E. coli numbering.
- 13. The method of claim 1, wherein said compound is designed de novo.
- 14. The method of claim 1, wherein said compound is designed from a known compound.
- 15. The method of claim 14 wherein said known compound is selected from the group consisting of antibiotics, initiation factors, and elongation factors.
- 16. The method of claim 15, wherein said antibiotics are selected from the group consisting of paromomycin, puromycin, streptomycin, neomycin, thiostrepton, micrococcin, fusidic acid, kirromycin, chloramphenicol, clindamycin, erythromycin, clarithromycin, and roxithromycin.
- 17. The method of claim 15, wherein said initiation factors are selected from the group consisting of IF1, IF2, and IF3.
- 18. The method of claim 15, wherein said elongation factors are selected from the group consisting of EF-Tu, and EF-G.
- 19. The method of claim 1, further comprising the step of determining whether the designed compound inhibits protein translation.
- 20. The method of claim 1, further comprising the step of determining whether the designed compound alters protein translation fidelity.
- 21. The method of claim 1, further comprising the step of determining whether the designed compound affects association between a 30S and a 50S ribosome subunit.
- 22. The method of claim 1, further comprising the step of determining whether the designed compound affects binding of a tRNA to a ribosomal tRNA binding site.
- 23. The method of claim 1, further comprising the step of determining whether the designed compound affects binding of an mRNA to a ribosomal mRNA binding site.
- 24. The method of claim 1, further comprising the step of determining whether the designed compound affects binding of IF3 to a ribosomal IF3 binding site.
- 25. The method of claim 1, further comprising the step of determining whether the designed compound affects binding of EF-Tu to a ribosomal EF-Tu ribosomal binding site.
- 26. The method of claim 1, further comprising the step of determining whether the designed compound affects binding of EF-G to a ribosomal EF-G ribosomal binding site.
- 27. A method of identifying a compound that binds to a bacterial 70S ribosome or portion thereof, comprising:
obtaining a set of structure coordinates defining the three-dimensional structure of a crystal of a bacterial 70S ribosome that diffracts X-rays for the determination of the structure coordinates of the bacterial 70S ribosome to a resolution of at least 5.5 Angstroms, wherein said bacterial 70S ribosome comprises a 23S rRNA having residues 1-2916 of SEQ ID NO: 23, a 5S rRNA having residues 1-123 of SEQ ID NO: 24, and a 16S rRNA having residues 1-1522 of SEQ ID NO: 45, and wherein said crystal has a space group of 1422 with unit cell dimensions of a=b=507.2 Angstroms, and c=803.7 Angstroms; designing a compound based upon the structure coordinates obtained from said crystal; providing said compound; contacting said compound with the 70S ribosome or portion thereof; and determining whether said compound binds to the bacterial 70S ribosome or portion thereof.
- 28. The method of claim 27, wherein a subset of the structure coordinates obtained from said crystal is used for said designing step.
- 29. The method of claim 27, wherein said portion is a bacterial ribosome 30S subunit.
- 30. The method of claim 27, wherein said portion is a bacterial ribosome 50S subunit.
- 31. The method of claim 27, wherein said compound is designed de novo.
- 32. The method of claim 27, wherein said compound is designed from a known compound.
- 33. The method of claim 32 wherein said known compound is selected from the group consisting of antibiotics, initiation factors, and elongation factors.
- 34. The method of claim 33, wherein said antibiotics are selected from the group consisting of paromomycin, puromycin, streptomycin, neomycin, thiostrepton, micrococcin, fusidic acid, kirromycin, chloramphenicol, clindamycin, erythromycin, clarithromycin, and roxithromycin.
- 35. The method of claim 33, wherein said initiation factors are selected from the group consisting of IF1, IF2, and IF3.
- 36. The method of claim 33, wherein said elongation factors are selected from the group consisting of EF-Tu and EF-G.
- 37. The method of claim 27, further comprising the step of determining whether the designed compound inhibits protein translation.
- 38. The method of claim 27, further comprising the step of determining whether the designed compound alters protein translation fidelity.
- 39. The method of claim 27, further comprising the step of determining whether the designed compound affects association between a 30S and a 50S ribosome subunit.
- 40. The method of claim 27, further comprising the step of determining whether the designed compound affects binding of a tRNA to a ribosomal tRNA binding site.
- 41. The method of claim 27, further comprising the step of determining whether the designed compound affects binding of an mRNA to a ribosomal mRNA binding site.
- 42. The method of claim 27, further comprising the step of determining whether the designed compound affects binding of IF3 to a ribosomal IF3 binding site.
- 43. The method of claim 27, further comprising the step of determining whether the designed compound affects binding of EF-Tu to a ribosomal EF-Tu ribosomal binding site.
- 44. The method of claim 27, further comprising the step of determining whether the designed compound affects binding of EF-G to a ribosomal EF-G ribosomal binding site.
- 45. A computer system comprising:
a memory comprising X-ray crystallographic structure coordinates defining at least a portion of a bacterial 70S ribosome, said structure coordinates determined from a crystal of a bacterial 70S ribosome that diffracts X-rays to a resolution of at least 5.5 Angstroms and having a space group of 1422 with unit cell dimensions of a=b=507.2 Angstroms, and c=803.7 Angstroms; and a processor in electrical communication with the memory; wherein the processor generates a molecular model having a three dimensional shape representative of at least a portion of said bacterial 70S ribosome.
- 46. The system of claim 45, wherein said molecular model comprises a three-dimensional solvent accessible surface representative of at least a portion of said bacterial 70S ribosome.
- 47. The system of claim 45, wherein said molecular model is representative of at least a portion of an interface between a 30S and a 50S subunit.
- 48. The system of claim 45, wherein said molecular model is representative of a binding site selected from the group consisting of an mRNA binding site, a tRNA binding site, an initiation factor binding site, an elongation factor binding site, and an antibiotic binding site.
- 49. The system of claim 48, wherein said binding site is an mRNA binding site.
- 50. The system of claim 48, wherein said binding site is a tRNA binding site.
- 51. The system of claim 48, wherein said binding site is an initiation factor binding site.
- 52. The system of claim 48, wherein said binding site is an elongation factor binding site.
- 53. The system of claim 48, wherein said binding site is an antibiotic binding site.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/254,603, filed Dec. 9, 2000, U.S. Provisional Application No. 60, 278,013, filed Mar. 22, 2001, and U.S. Provisional Application No. 60/294,394 filed May 30, 2001, the entire disclosure of each of which is hereby incorporated by reference in its entirety for all purposes.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under GM-17129 and GM-59140 awarded by the National Institutes of Health. The government has certain rights in the invention.
Provisional Applications (3)
|
Number |
Date |
Country |
|
60254603 |
Dec 2000 |
US |
|
60278013 |
Mar 2001 |
US |
|
60294394 |
May 2001 |
US |